Sorafenib Plus Intensive Chemotherapy Improves Outcomes in FLT3-Mutated Acute Myeloid Leukemia
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Acute Myeloid Leukemia
Older Adults With AML Can Achieve Long-Term Survival After Intensive Chemotherapy, ICU Admission
Approximately 30% of older patients with AML who had or were receiving active treatment were admitted to the ICU. This study sought to determine overall survival for these patients.
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Heparin Derivative CX-01 May Boost Standard AML Induction
The new findings suggest that CX-01 may strengthen the efficacy of standard AML induction.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Update from AACR: Divergent Data on FLT3 Inhibitors Tell a Tale of 2 Outcomes in AML and mCRC
Several preclinical studies provided more refined and nuanced insights into the target itself, and bioinformatics uncovered a way to measure low levels of residual disease during morphologic remission.
Similar Health Care Costs in Older Patients With AML Regardless of Induction Intensity
A similar number of transfusions were required in older patients with AML receiving intensive induction therapy versus single-agent azacitadine or decitabine.
FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee recently voted on 2 investigational therapies being developed by Daiichi Sankyo: pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), and quizartinib for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).
Predicting Survival of Certain Subgroups of Patients With AML Following Allogeneic SCT
Based on the results of this study, a new risk stratification system was developed to facilitate prediction of posttransplant survival in patients with AML-MDC.
Next post in Hematologic Cancers
